Jeff Ajer, Executive Vice President and Chief Commercial Officer of BioMarin, discusses gene therapy. The development of these transformative therapies has triggered discussions about market access challenges, the viability of alternative financing mechanisms, and the results for patient access.

In this video, Mr. Ajer suggests that BioMarin will offer alternative funding mechanisms and payment structures. While gene therapies hold the promise of substantial benefits, some patients may face barriers accessing them.